Loading...
Clearside Biomedical Community
NasdaqGM:CLSD Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 5 Fair Values set on narratives written by author
Community Investing Ideas
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Key Takeaways FDA alignment on CLS-AX for wet AMD and Phase 2b outcomes may boost revenues and market leadership upon approval. Global partnerships and SCS technology expansions could enhance international market presence and revenue streams.Read more
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$60
93.9% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue growth
38.16% p.a.
Profit Margin
23.22%
Future PE
149.46x
Share price in 2028
US$65.66
Aging Global Population Will Boost Ocular Treatment Adoption
Key Takeaways Leading drug delivery technology, strong clinical results, and global partnerships could drive rapid adoption, robust licensing income, and significant revenue and margin expansion. Diversified pipeline and growing disease prevalence ensure long-term product launches, revenue diversification, and strong potential for transformative partnerships with next-generation therapy developers.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$6
38.7% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue growth
115.15% p.a.
Profit Margin
23.22%
Future PE
68.61x
Share price in 2028
US$7.59